David Sidransky - 13 Jun 2022 Form 4 Insider Report for Ayala Pharmaceuticals, Inc.

Role
Director
Signature
/s/ Roni Mamluk, Ph.D., Attorney-in-Fact for David Sidransky
Issuer symbol
N/A
Transactions as of
13 Jun 2022
Net transactions value
$0
Form type
4
Filing time
15 Jun 2022, 16:15:35 UTC
Previous filing
14 Feb 2022
Next filing
14 Oct 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AYLA Stock Option (Right to Buy) Award $0 +12,500 $0.000000 12,500 13 Jun 2022 Common Stock 12,500 $1.63 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.